ERBB2 and breast cancer: In this sense, high HER2 autoantibody levels have been described to possess a protective effect in BC, associated to a reduced risk of HER2+ BC subtype, and a better recurrence-survival rate after a 6-3686 day interval follow-up study of BC patients (84).